Olutasidenib
Olutasidenib 150 mg BID
150 mg · Single arm
relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)
objective response rate: 8%, 2 of 25
Olutasidenib Phase 1/2 (glioma cohort) · NCT03684811
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
4 arms have a reported figure in this set.
Olutasidenib 150 mg BID
150 mg · Single arm
relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)
objective response rate: 8%, 2 of 25
Olutasidenib Phase 1/2 (glioma cohort) · NCT03684811
Safusidenib 250 mg BID
250 mg · Single arm
IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)
confirmed objective response rate: 51.9%, median follow-up 38.8 months
J201 Phase 2 · NCT04458272
Vorasidenib 40 mg daily
40 mg · ITT
grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)
Comparator: placebo
objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary
INDIGO · NCT04164901
Vorasidenib, non-enhancing glioma
Phase 1 doses · Single arm
recurrent non-enhancing IDH-mutant glioma (n = 22)
objective response rate: 18%, Phase 1
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.